Keyword: Len Schleifer

Regeneron

4. Leonard “Len” Schleifer

Regeneron's Praluent lagged far behind sales expectations, and it lost a patent trial. Company shares began to slide in late 2016, and that’s why Len Schleifer’s pay declined in 2016.
Person offering money

The top 15 highest-paid biopharma executives

Some of the executive pay rankings are predictable, like Johnson & Johnson's CEO, regardless who's in the job. What's not guaranteed is that the chairman of a generics maker in hot water with the U.S. government and American parents—Mylan's Robert Coury—would step off the company’s employee roster and into the nonexecutive chairman’s job and reap a $97 million package with the move.